Although this decrease in fracture incidence in the treated group may be associated with increased awareness and new osteoporosis treatments (bisphosphonates, teriparatide), this study provides significant results in evaluating the long-term efficacy of GH treatment in postmenopausal osteoporosis [64]. The gene discussed is GH1; the disease is osteoporosis.